FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044382189> ?p ?o ?g. }

• W3044382189 endingPage "2035" @default.
• W3044382189 startingPage "2035" @default.
• W3044382189 abstract "TO THE EDITOR: Individuals with chronic obstructive pulmonary disease (COPD) have previously been identified to have an elevated serum level of angiotensin-converting enzyme 2 (ACE2), the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The newest discoveries by Higham et al. ((1)) were the increased ACE2 expression in the bronchial epithelium of overweight patients with COPD compared with their nonoverweight counterparts. Given the fact that higher expression of ACE2 may lead to an increased risk of a severe course of coronavirus disease (COVID-19), there are potential benefits of using angiotensin receptor blockers (ARBs) among overweight patients with COPD. In its native state, the angiotensin type I receptor (AT1R) binds to ACE2 to form a receptor complex ((2)). Administration of ARBs could then stabilize the ACE2-AT1 receptor complex on the cell membrane and thus prevent interaction of SARS-CoV-2 with the ACE2 catalytic site. Even if ARBs could not eliminate the cellular viral entry, ARBs could also block the binding of excess angiotensin II (from downregulation of ACE2 following a hijack by SARS-CoV-2) to AT1R and thus mitigate angiotensin II–mediated lung injury and subsequent development of acute respiratory failure. In addition, ARBs possess anti-inflammatory actions with their ability to utilize the ACE2/angiotensin II type 2 receptor/Mas receptor pathway that could limit the cytokine storm induced by SARS-CoV-2. On the contrary, many may not recognize the effects of ARBs on body weight. Specifically, telmisartan could prevent adipogenesis and weight gain. Telmisartan has been shown to upregulate the expression and activity of peroxisome proliferator–activated receptor (PPAR)-δ in 3T3-L1 preadipocytes in a dose-dependent fashion. The subsequent activation of PPAR-δ–dependent lipolytic pathway by telmisartan reduced adipogenesis in vitro ((3)). In vivo, long-term administration of telmisartan significantly reduced the increase in body weight and prevented high-fat diet-induced obesity through increased expression of PPAR-δ and several lipolytic and energy uncoupling-related proteins in adipose tissue and skeletal muscle in wild-type mice and spontaneously hypertensive rats ((3)). In fact, a human study of 32 patients with type 2 diabetes and metabolic syndrome who received telmisartan demonstrated a significant decline in BMI as well as waist circumference at 6 months compared with baseline ((4)). We are aware of some human and animal studies showing an increased ACE2 expression with the administration of ARBs other than telmisartan, but such observations may not translate to a greater susceptibility toward COVID-19. Specifically, a study that included only 1.6% (621/37,031) of patients with COPD reported no difference in the risk of acquisition of COVID-19 between ARB users and non-ARB users, though the protective effect of ARBs toward the acquisition of COVID-19 may be more apparent among patients with overweight and COPD who may have a higher baseline risk of acquisition of COVID-19 ((5)). We recognize that no evidence thus far has shown that ARBs or specifically telmisartan could prevent or lead to better clinical outcomes among overweight patients with COPD upon acquisition of COVID-19. Nevertheless, we hope that this discussion of the potential effects of telmisartan can serve to stimulate an interest to trial telmisartan for the prevention and management of COVID-19 in overweight patients with COPD because of its dual benefits to prevent/mitigate COVID-19 and to induce weight loss in this patient population. The authors declared no conflict of interest." @default.
• W3044382189 created "2020-07-29" @default.
• W3044382189 creator A5070482896 @default.
• W3044382189 creator A5076366979 @default.
• W3044382189 date "2020-09-23" @default.
• W3044382189 modified "2023-09-27" @default.
• W3044382189 title "The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID‐19" @default.
• W3044382189 cites W1964387349 @default.
• W3044382189 cites W2104620139 @default.
• W3044382189 cites W3023640683 @default.
• W3044382189 cites W3024012124 @default.
• W3044382189 cites W1997331869 @default.
• W3044382189 doi "https://doi.org/10.1002/oby.22976" @default.
• W3044382189 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7404622" @default.
• W3044382189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32692903" @default.
• W3044382189 hasPublicationYear "2020" @default.
• W3044382189 type Work @default.
• W3044382189 sameAs 3044382189 @default.
• W3044382189 citedByCount "1" @default.
• W3044382189 countsByYear W30443821892023 @default.
• W3044382189 crossrefType "journal-article" @default.
• W3044382189 hasAuthorship W3044382189A5070482896 @default.
• W3044382189 hasAuthorship W3044382189A5076366979 @default.
• W3044382189 hasBestOaLocation W30443821891 @default.
• W3044382189 hasConcept C123915805 @default.
• W3044382189 hasConcept C126322002 @default.
• W3044382189 hasConcept C134018914 @default.
• W3044382189 hasConcept C170493617 @default.
• W3044382189 hasConcept C198710026 @default.
• W3044382189 hasConcept C203014093 @default.
• W3044382189 hasConcept C2775946041 @default.
• W3044382189 hasConcept C2776780178 @default.
• W3044382189 hasConcept C2777648638 @default.
• W3044382189 hasConcept C2779134260 @default.
• W3044382189 hasConcept C2779716603 @default.
• W3044382189 hasConcept C2780586474 @default.
• W3044382189 hasConcept C2908929049 @default.
• W3044382189 hasConcept C3008058167 @default.
• W3044382189 hasConcept C511355011 @default.
• W3044382189 hasConcept C524204448 @default.
• W3044382189 hasConcept C71924100 @default.
• W3044382189 hasConcept C84393581 @default.
• W3044382189 hasConceptScore W3044382189C123915805 @default.
• W3044382189 hasConceptScore W3044382189C126322002 @default.
• W3044382189 hasConceptScore W3044382189C134018914 @default.
• W3044382189 hasConceptScore W3044382189C170493617 @default.
• W3044382189 hasConceptScore W3044382189C198710026 @default.
• W3044382189 hasConceptScore W3044382189C203014093 @default.
• W3044382189 hasConceptScore W3044382189C2775946041 @default.
• W3044382189 hasConceptScore W3044382189C2776780178 @default.
• W3044382189 hasConceptScore W3044382189C2777648638 @default.
• W3044382189 hasConceptScore W3044382189C2779134260 @default.
• W3044382189 hasConceptScore W3044382189C2779716603 @default.
• W3044382189 hasConceptScore W3044382189C2780586474 @default.
• W3044382189 hasConceptScore W3044382189C2908929049 @default.
• W3044382189 hasConceptScore W3044382189C3008058167 @default.
• W3044382189 hasConceptScore W3044382189C511355011 @default.
• W3044382189 hasConceptScore W3044382189C524204448 @default.
• W3044382189 hasConceptScore W3044382189C71924100 @default.
• W3044382189 hasConceptScore W3044382189C84393581 @default.
• W3044382189 hasIssue "11" @default.
• W3044382189 hasLocation W30443821891 @default.
• W3044382189 hasLocation W30443821892 @default.
• W3044382189 hasLocation W30443821893 @default.
• W3044382189 hasOpenAccess W3044382189 @default.
• W3044382189 hasPrimaryLocation W30443821891 @default.
• W3044382189 hasRelatedWork W1974641745 @default.
• W3044382189 hasRelatedWork W2016647631 @default.
• W3044382189 hasRelatedWork W2038571733 @default.
• W3044382189 hasRelatedWork W2042660006 @default.
• W3044382189 hasRelatedWork W2048334412 @default.
• W3044382189 hasRelatedWork W2069444929 @default.
• W3044382189 hasRelatedWork W2126797993 @default.
• W3044382189 hasRelatedWork W2591366330 @default.
• W3044382189 hasRelatedWork W4247631657 @default.
• W3044382189 hasRelatedWork W1520407786 @default.
• W3044382189 hasVolume "28" @default.
• W3044382189 isParatext "false" @default.
• W3044382189 isRetracted "false" @default.
• W3044382189 magId "3044382189" @default.
• W3044382189 workType "article" @default.